Astrazeneca (AZN) Total Debt (2009 - 2025)

Astrazeneca (AZN) has reported Total Debt for 17 consecutive years, with -$21.6 billion the latest figure, recorded in FY2025.

• In Q1 2026, Total Debt rose 8.38% year-over-year to -$24.5 billion; the TTM figure through Mar 2026 stood at -$24.5 billion (up 8.38% YoY), while the FY2025 annual figure was -$21.6 billion, down 174.93% from the prior year.
• Total Debt came in at -$21.6 billion for FY2025 at Astrazeneca, down from $28.8 billion in the prior year.
• The five-year high for Total Debt was $29.8 billion in FY2021, with the low at -$21.6 billion in FY2025.
• Average Total Debt over 5 years is $18.6 billion, with a median of $28.3 billion recorded in 2022.
• Across the five-year window, Total Debt soared 321.89% in 2021 and slumped 174.93% in 2025, its largest moves.
• Year by year, Total Debt stood at $29.8 billion in 2021, then retreated by 5.08% to $28.3 billion in 2022, then slipped by 2.78% to $27.5 billion in 2023, then gained by 4.91% to $28.8 billion in 2024, then sank by 174.93% to -$21.6 billion in 2025.
• According to Business Quant data, Total Debt over the past three periods registered -$21.6 billion, $28.8 billion, and $27.5 billion for FY2025, FY2024, and FY2023 respectively.